share_log

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga ·  Mar 26 01:30

Gainers

  • Landos Biopharma (NASDAQ:LABP) shares rose 173.9% to $21.45 during Monday's regular session. The market value of their outstanding shares is at $66.8 million. The company's, Q4 earnings came out 2 days ago.
  • Altamira Therapeutics (NASDAQ:CYTO) stock moved upwards by 30.63% to $2.26. The market value of their outstanding shares is at $4.1 million.
  • XTL Biopharmaceuticals (NASDAQ:XTLB) shares increased by 28.24% to $3.36. The company's market cap stands at $18.3 million.
  • Nkarta (NASDAQ:NKTX) shares moved upwards by 23.87% to $11.05. The company's market cap stands at $542.2 million. As per the news, the Q4 earnings report came out 2 days ago.
  • Sagimet Biosciences (NASDAQ:SGMT) stock rose 23.05% to $5.55. The market value of their outstanding shares is at $177.0 million. The company's, FY earnings came out today.
  • Molecular Templates (NASDAQ:MTEM) shares moved upwards by 21.62% to $2.25. The company's market cap stands at $12.0 million.

Losers

  • Trxade Health (NASDAQ:MEDS) stock decreased by 48.6% to $12.38 during Monday's regular session. The company's market cap stands at $14.9 million.
  • SINTX Techs (NASDAQ:SINT) stock declined by 48.01% to $0.05.
  • Akanda (NASDAQ:AKAN) stock decreased by 34.42% to $0.16. The market value of their outstanding shares is at $1.4 million.
  • Invivyd (NASDAQ:IVVD) stock declined by 23.06% to $3.35. The company's market cap stands at $398.7 million.
  • 180 Life Sciences (NASDAQ:ATNF) stock fell 19.88% to $2.22. The market value of their outstanding shares is at $1.6 million.
  • Kineta (NASDAQ:KA) shares decreased by 16.88% to $0.54. The market value of their outstanding shares is at $5.6 million. The company's, Q4 earnings came out 2 days ago.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment